Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer
CTR20170251Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pyrotinib, lapatinib, capecitabine in HER2-positive breast cancer, sponsored by Hengrui Therapeutics. Started Jul 2017; status: active.
02
Drugs
pyrotiniblapatinibcapecitabine
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on CTR20170251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170251.